# A Clinical Study of the Efficacy and Safety of Disitamab Vedotin in Combination With Radiotherapy for the Adjuvant Treatment of HER2 Overexpressing UTUC Patients With High Risk Factors for Recurrence After Radical Surgery

> **NCT06210490** · PHASE2 · RECRUITING · sponsor: **Peking University First Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Upper Urinary Tract Urothelial Carcinoma

## Interventions

- **DRUG:** Disitamab Vedotin
- **RADIATION:** Radiotherapy
- **OTHER:** Standard of Care

## Key facts

- **NCT ID:** NCT06210490
- **Lead sponsor:** Peking University First Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-20
- **Primary completion:** 2028-05-31
- **Final completion:** 2028-05-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06210490

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06210490, "A Clinical Study of the Efficacy and Safety of Disitamab Vedotin in Combination With Radiotherapy for the Adjuvant Treatment of HER2 Overexpressing UTUC Patients With High Risk Factors for Recurrence After Radical Surgery". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06210490. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*